NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
7.97
+0.41 (5.42%)
At close: Nov 16, 2026, 4:00 PM EST
7.82
-0.15 (-1.88%)
After-hours: Nov 16, 2026, 7:39 PM EST
NeuroPace Revenue
NeuroPace had revenue of $23.10M in the quarter ending September 30, 2026, a decrease of -1.06%. This brings the company's total for the last twelve months to $94.59M, up 8.92% year-over-year. In the year 2025, NeuroPace had annual revenue of $99.99M with 25.13% growth. That makes NeuroPace the 22,213th largest company in the world by revenue and 3,248th in the United States.
Revenue (ttm)
$94.59M
Revenue Growth
+8.92%
P/S Ratio
2.57
Revenue / Employee
$494,194
Employees
216
Market Cap
274.58M
Revenue by Geography
- United States 99.09M 99.1%
- Foreign 900.00K 0.9%
Fiscal year ended Dec 31, 2025 See the full NeuroPace breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.99M | 20.08M | 25.13% |
| Dec 31, 2024 | 79.91M | 14.49M | 22.14% |
| Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
| Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
| Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
| Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
| Dec 31, 2019 | 36.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 835.41M |
| Treace Medical Concepts | 203.35M |
| InfuSystem Holdings | 144.44M |
| RxSight | 121.83M |
| Standard BioTools | 84.43M |
| Electromed | 75.57M |
| SS Innovations International | 52.40M |
| ClearPoint Neuro | 45.49M |
NPCE News
- 18 hours ago - NeuroPace price target lowered to $12 from $22 at Mizuho - TheFly
- 19 hours ago - NeuroPace price target lowered to $12 from $20 at H.C. Wainwright - TheFly
- 3 days ago - Leerink downgrades NeuroPace amid commercial setbacks, cuts to growth outlook - TheFly
- 3 days ago - NeuroPace price target lowered to $13 from $20 at Lake Street - TheFly
- 3 days ago - NeuroPace downgraded to Equal Weight from Overweight at Wells Fargo - TheFly
- 3 days ago - NeuroPace price target lowered to $14 from $18 at KeyBanc - TheFly
- 3 days ago - NeuroPace downgraded to Neutral from Overweight at JPMorgan - TheFly
- 3 days ago - NeuroPace downgraded to Market Perform from Outperform at Leerink - TheFly